Q2 2024 · 13F-HR
Artia Global Partners LPholdings as filed
Filed 2024-08-14 · accession 0001937964-24-000005
$517.3M
Reported value
46
Positions
2024-06-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 670100205 | NVO | NOVO-NORDISK A S | $98.7M | 19.1% | 691,743 | Common | SOLE |
| 532457108 | LLY | ELI LILLY & CO | $83.8M | 16.2% | 92,593 | Common | SOLE |
| 532457958 | — | ELI LILLY & CO | $67.9M | 13.1% | 75,000 | PUT | SOLE |
| 58933Y105 | MRK | MERCK & CO INC | $54.8M | 10.6% | 442,504 | Common | SOLE |
| 670100955 | — | NOVO-NORDISK A S | $44.2M | 8.55% | 310,000 | PUT | SOLE |
| 92686J106 | VKTX | VIKING THERAPEUTICS INC | $24.0M | 4.64% | 452,979 | Common | SOLE |
| 046353108 | AZNN | ASTRAZENECA PLC | $14.9M | 2.88% | 190,752 | Common | SOLE |
| 46116X101 | ITCIEUR | INTRA-CELLULAR THERAPIES INC | $14.8M | 2.87% | 216,519 | Common | SOLE |
| 92532F100 | VRTX | VERTEX PHARMACEUTICALS INC | $8.9M | 1.71% | 18,900 | Common | SOLE |
| 02043Q107 | ALNY | ALNYLAM PHARMACEUTICALS INC | $8.5M | 1.64% | 35,000 | Common | SOLE |
| 92686J906 | — | VIKING THERAPEUTICS INC | $8.0M | 1.54% | 150,000 | CALL | SOLE |
| 457669957 | — | INSMED INC | $7.4M | 1.42% | 110,000 | PUT | SOLE |
| 05464T104 | AXSM | AXSOME THERAPEUTICS INC | $7.1M | 1.37% | 87,848 | Common | SOLE |
| 04016X101 | ARGX | ARGENX SE | $6.5M | 1.26% | 15,138 | Common | SOLE |
| 64125C109 | NBIX | NEUROCRINE BIOSCIENCES INC | $6.2M | 1.20% | 45,000 | Common | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $5.8M | 1.11% | 76,255 | Common | SOLE |
| 74366E102 | PTGX | PROTAGONIST THERAPEUTICS INC | $4.3M | 0.83% | 124,440 | Common | SOLE |
| 26818M108 | DYN | DYNE THERAPEUTICS INC | $4.2M | 0.82% | 119,488 | Common | SOLE |
| 834203309 | SLNO | SOLENO THERAPEUTICS INC | $3.9M | 0.74% | 94,424 | Common | SOLE |
| 22663K107 | CRNX | CRINETICS PHARMACEUTICALS IN | $3.8M | 0.74% | 85,765 | Common | SOLE |
| 457669307 | INSM | INSMED INC | $3.6M | 0.69% | 53,436 | Common | SOLE |
| 67576A100 | OCUL | OCULAR THERAPEUTIX INC | $3.4M | 0.66% | 500,000 | Common | SOLE |
| 462222100 | IONS | IONIS PHARMACEUTICALS INC | $3.0M | 0.58% | 62,479 | Common | SOLE |
| N5749R100 | 2GH | MERUS N V | $3.0M | 0.57% | 50,171 | Common | SOLE |
| 15117B202 | CLDX | CELLDEX THERAPEUTICS INC NEW | $2.8M | 0.54% | 75,300 | Common | SOLE |
| 03770N101 | APGE | APOGEE THERAPEUTICS INC | $2.3M | 0.44% | 58,400 | Common | SOLE |
| 85205L107 | SWTXUSD | SPRINGWORKS THERAPEUTICS INC | $2.0M | 0.39% | 53,930 | Common | SOLE |
| 45166A102 | IDYA | IDEAYA BIOSCIENCES INC | $1.9M | 0.37% | 54,392 | Common | SOLE |
| 925050106 | VRNA | VERONA PHARMA PLC | $1.9M | 0.37% | 130,790 | Common | SOLE |
| 98420N105 | XENE | XENON PHARMACEUTICALS INC | $1.6M | 0.30% | 40,000 | Common | SOLE |
| 589492107 | MREO | MEREO BIOPHARMA GROUP PLC | $1.5M | 0.29% | 421,359 | Common | SOLE |
| 159864107 | CRL | CHARLES RIV LABS INTL INC | $1.4M | 0.28% | 6,905 | Common | SOLE |
| 50127T109 | KURA | KURA ONCOLOGY INC | $1.2M | 0.23% | 57,178 | Common | SOLE |
| N62509109 | NAMS | NEWAMSTERDAM PHARMA COMPANY | $1.0M | 0.20% | 54,285 | Common | SOLE |
| 04351P101 | ASNDUSD | ASCENDIS PHARMA A/S | $1.0M | 0.20% | 7,440 | Common | SOLE |
| 82686Q101 | SLN | SILENCE THERAPEUTICS PLC | $997,044 | 0.19% | 52,476 | Common | SOLE |
| 87164F105 | SNDX | SYNDAX PHARMACEUTICALS INC | $990,839 | 0.19% | 48,263 | Common | SOLE |
| 492327101 | KROS | KEROS THERAPEUTICS INC | $914,000 | 0.18% | 20,000 | Common | SOLE |
| 21833P301 | CRBP | CORBUS PHARMACEUTICALS HLDGS | $905,000 | 0.17% | 20,000 | Common | SOLE |
| 30233G209 | EYPT | EYEPOINT PHARMACEUTICALS INC | $883,050 | 0.17% | 101,500 | Common | SOLE |
| 03589W102 | ANNX | ANNEXON INC | $722,677 | 0.14% | 147,485 | Common | SOLE |
| 517125100 | LRMR | LARIMAR THERAPEUTICS INC | $656,053 | 0.13% | 90,490 | Common | SOLE |
| 254604101 | IRON | DISC MEDICINE INC | $605,741 | 0.12% | 13,440 | Common | SOLE |
| 729139105 | PLRX | PLIANT THERAPEUTICS INC | $537,500 | 0.10% | 50,000 | Common | SOLE |
| 558868105 | MDGL | MADRIGAL PHARMACEUTICALS INC | $436,209 | 0.08% | 1,557 | Common | SOLE |
| 803607100 | SRPT | SAREPTA THERAPEUTICS INC | $410,800 | 0.08% | 2,600 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.